$5.08
4.31% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US98422L1070
Symbol
XERS
Sector
Industry

Xeris Pharmaceuticals Inc Stock price

$5.08
+1.06 26.37% 1M
+2.02 66.01% 6M
+1.69 49.85% YTD
+3.03 147.80% 1Y
+2.91 134.10% 3Y
+0.65 14.67% 5Y
-15.14 74.88% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.21 4.31%
ISIN
US98422L1070
Symbol
XERS
Sector
Industry

Key metrics

Market capitalization $813.59m
Enterprise Value $1.02b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.60
P/S ratio (TTM) P/S ratio 3.66
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 29.88%
Revenue (TTM) Revenue $222.55m
EBIT (operating result TTM) EBIT $-22.49m
Free Cash Flow (TTM) Free Cash Flow $-27.43m
Cash position $58.44m
EPS (TTM) EPS $-0.30
P/E forward negative
P/S forward 3.03
EV/Sales forward 3.82
Short interest 11.19%
Show more

Is Xeris Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Xeris Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Xeris Pharmaceuticals Inc forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Xeris Pharmaceuticals Inc forecast:

Buy
83%
Hold
17%

Financial data from Xeris Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
223 223
30% 30%
100%
- Direct Costs 50 50
26% 26%
23%
172 172
31% 31%
77%
- Selling and Administrative Expenses 157 157
14% 14%
70%
- Research and Development Expense 25 25
1% 1%
11%
-9.94 -9.94
69% 69%
-4%
- Depreciation and Amortization 13 13
5% 5%
6%
EBIT (Operating Income) EBIT -22 -22
50% 50%
-10%
Net Profit -45 -45
30% 30%
-20%

In millions USD.

Don't miss a Thing! We will send you all news about Xeris Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xeris Pharmaceuticals Inc Stock News

Neutral
Business Wire
about 17 hours ago
CHICAGO--(BUSINESS WIRE)--Xeris Announces Details for Analyst & Investor Day.
Neutral
Seeking Alpha
12 days ago
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pieper - CFO Conference Call Participants David Amsellem - Piper Sandler Eason Lee - Leerink Partners Jason Dorr - Oppenheimer Chase Knickerbocker - Craig-Hallum Operator Good morning. Thank you for a...
Neutral
Business Wire
13 days ago
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. “We're very pleased with our stro...
More Xeris Pharmaceuticals Inc News

Company Profile

Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL.

Head office United States
CEO John Shannon
Employees 394
Founded 2005
Website www.xerispharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today